Influence of Preexisting Psychiatric Morbidity on Liothyronine Use in Hypothyroidism: A Swedish Nationwide Cohort Study
Open Access
- 7 June 2025
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (1) , e100-e105
Abstract
Context: Autoimmune hypothyroidism is a common endocrine disorder affecting 1% to 2% of the population in iodine sufficient areas. While levothyroxine is standard treatment, a substantial number of patients report persistent symptoms despite adequate treatment. The use of liothyronine as an adjunct to levothyroxine therapy has increased. The psychiatric characteristics of patients receiving liothyronine remain largely unknown. Objective: This study examines the association between preexisting psychiatric morbidity and subsequent liothyronine use in autoimmune hypothyroidism. Methods: This nationwide retrospective cohort study includes all adults in Sweden with autoimmune hypothyroidism and initiated on treatment with thyroid hormones between 2006 and 2020. Data were obtained from the National Patient Register and the National Prescribed Drug Register. Psychiatric morbidity prior to diagnosis was identified using ICD-10 codes and ATC codes for psychiatric medications. Logistic models estimated associations, adjusting for sex, age, and region. Results: Among 353 708 patients, 44.8% had a history of psychiatric morbidity. These patients were more likely to receive liothyronine (adjusted odds ratio [aOR] 1.90, 95% CI 1.83-1.97, P < .001) than those without a psychiatric history. This was most evident among individuals with affective or anxiety morbidity (aOR 1.91, 95% CI 1.84-1.98, P < .001). No association was found for psychotic morbidity (aOR 1.08, 95% CI 0.98-1.19, P = .11). Conclusion: Patients with a psychiatric history before autoimmune hypothyroidism were more likely to receive liothyronine, especially among those with affective or anxiety morbidity. This may reflect persistent symptoms and affect subsequent decisions in the treatment of hypothyroidism.Keywords
Funding Information
- Region Stockholm Drug and Therapeutic Committee
- the Lisa and Johan Grönberg Foundation (2022-00220)
- the Lisa and Johan Grönberg Foundation (2023-007)
This publication has 26 references indexed in Scilit:
- Subclinical thyroid dysfunction and major depressive disorderHormones, 2021
- The echo chamber effect on social mediaProceedings of the National Academy of Sciences of the United States of America, 2021
- Physician Choice of Hypothyroidism Therapy: Influence of Patient CharacteristicsThyroid®, 2018
- Global epidemiology of hyperthyroidism and hypothyroidismNature Reviews Endocrinology, 2018
- Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone ReplacementThyroid®, 2014
- Increased Psychiatric Morbidity Before and After the Diagnosis of Hypothyroidism: A Nationwide Register StudyThyroid®, 2014
- Paradigm shifts in thyroid hormone replacement therapies for hypothyroidismNature Reviews Endocrinology, 2014
- The Swedish personal identity number: possibilities and pitfalls in healthcare and medical researchEuropean Journal of Epidemiology, 2009
- The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six monthsPharmacoepidemiology and Drug Safety, 2006
- Increased Risk of Developing Affective Disorder in Patients with Hypothyroidism: A Register-Based StudyThyroid®, 2005